99.9% USP Bp Pirfenidone Powder CAS 53179 -13-8 Pharmaceutical Raws Pirfenidone
China 99.9% USP Bp Pirfenidone Powder CAS 53179-13-8 Pharmaceutical Raws Pirfenidone, Find details about China Pirfenidone, Pirfenidone Powder from 99.9% USP Bp Pirfenidone Powder CAS 53179-13-8 Pharmaceutical Raws Pirfenidone
Basic Info.
Model NO.
hupharma
Payment
Bitcoin/Wu/Mg/Wire Transfer
Minimum
10g
Delivery Time
1-3 Days
Shipping
Worldwide
Trademark
hupharma
Transport Package
Safe and Fast Delivery
Specification
10g, 100g, 1kg, 25kg
Origin
China
HS Code
2937290090
Model NO.
hupharma
Payment
Bitcoin/Wu/Mg/Wire Transfer
Minimum
10g
Delivery Time
1-3 Days
Shipping
Worldwide
Trademark
hupharma
Transport Package
Safe and Fast Delivery
Specification
10g, 100g, 1kg, 25kg
Origin
China
HS Code
2937290090
Product Desciption
99.9% USP BP Pirfenidone Powder CAS 53179-13-8 Pharmaceutical Raws Pirfenidone
99.9% USP BP Pirfenidone Powder CAS 53179-13-8 Pharmaceutical Raws Pirfenidone
99.9% USP BP Pirfenidone Powder CAS 53179-13-8 Pharmaceutical Raws Pirfenidone
Product Name: Pirfenidone
Synonyms: 5-Methyl-1-phenylpyridine-2(1H)-one;S-7701;5-methyl-1-phenyl-2-pyridone;5-methyl-1-phenyl-pyridin-2-one;5-methyl-1-phenylpyridin-2-one;Pirfenidone, >=99%;5-methyl-1-phenylpyridin-2(1H)-one;Pirfenidone(S-7701,AMR-69)
CAS: 53179-13-8
MF: C12H11NO
MW: 185.22
EINECS: 621-260-7
Appearance: white to pale yellow powder
Uses: Pirfenidone is a broad-spectrum antifibrotic drug that modulates diverse cytokine action involving TGF-β, TNF-α, epidermal growth factor, platelet-derived growth factor,vascular endothelial growth factor, insulin-like growth factor 1, fibroblast growth factor, and others.Pirfenidone has been effective in the prevention and regression of pulmonary fibrosis, peritoneal sclerosis, hepatic cirrhosis, uterine fibromyoma, and other scarring and fibrotic conditions. It doesn't cure the condition or reverse any existing scarring but it can effectively slow down the rate of lung function decline by about 50%. In the UK, Pirfenidone is currently only approved for treating IPF, and not for other forms of pulmonary fibrosis.
Pirfenidone (PFD) is a novel kind of pyridine ketones which has a broad-spectrum anti-fibrotic effect, being able to prevent and reverse the formation of fibrosis and scar. It entered into market in Shionogi, Japan in 2008 and has been approved by the US food and Drug Administration. It is the first drug which has gone through phase III clinical trials (including repeating, randomized, and placebo-control) which has demonstrates its effectiveness in treating idiopathic pulmonary fibrosis (IPF); moreover, the drug has relative good efficacy in treating some fibrotic diseases such as renal interstitial fibrosis and liver fibrosis. Furthermore, it is also widely applied in the phase II clinical study in kidney disease (focal segmental glomerulosclerosis), hypertrophic cardiomyopathy, adult type I neurofibromatosis, youth I type of neurofibromatosis and plexiform neurofibromas, diabetes together with kidney disease.
99.9% USP BP Pirfenidone Powder CAS 53179-13-8 Pharmaceutical Raws Pirfenidone
99.9% USP BP Pirfenidone Powder CAS 53179-13-8 Pharmaceutical Raws Pirfenidone
Product Name: Pirfenidone
Synonyms: 5-Methyl-1-phenylpyridine-2(1H)-one;S-7701;5-methyl-1-phenyl-2-pyridone;5-methyl-1-phenyl-pyridin-2-one;5-methyl-1-phenylpyridin-2-one;Pirfenidone, >=99%;5-methyl-1-phenylpyridin-2(1H)-one;Pirfenidone(S-7701,AMR-69)
CAS: 53179-13-8
MF: C12H11NO
MW: 185.22
EINECS: 621-260-7
Appearance: white to pale yellow powder
Uses: Pirfenidone is a broad-spectrum antifibrotic drug that modulates diverse cytokine action involving TGF-β, TNF-α, epidermal growth factor, platelet-derived growth factor,vascular endothelial growth factor, insulin-like growth factor 1, fibroblast growth factor, and others.Pirfenidone has been effective in the prevention and regression of pulmonary fibrosis, peritoneal sclerosis, hepatic cirrhosis, uterine fibromyoma, and other scarring and fibrotic conditions. It doesn't cure the condition or reverse any existing scarring but it can effectively slow down the rate of lung function decline by about 50%. In the UK, Pirfenidone is currently only approved for treating IPF, and not for other forms of pulmonary fibrosis.
Pirfenidone (PFD) is a novel kind of pyridine ketones which has a broad-spectrum anti-fibrotic effect, being able to prevent and reverse the formation of fibrosis and scar. It entered into market in Shionogi, Japan in 2008 and has been approved by the US food and Drug Administration. It is the first drug which has gone through phase III clinical trials (including repeating, randomized, and placebo-control) which has demonstrates its effectiveness in treating idiopathic pulmonary fibrosis (IPF); moreover, the drug has relative good efficacy in treating some fibrotic diseases such as renal interstitial fibrosis and liver fibrosis. Furthermore, it is also widely applied in the phase II clinical study in kidney disease (focal segmental glomerulosclerosis), hypertrophic cardiomyopathy, adult type I neurofibromatosis, youth I type of neurofibromatosis and plexiform neurofibromas, diabetes together with kidney disease.
You Might Also Like
Bounce House for Sale in Jiayuan Playground
6 Shelf Pantry Depot for Kitchen Cabinet Storage
Fashion Gemstone Crstal Carnelian Quartz Heart Keyring Penda......
Steel or Iron Door Hardware Fastener Hinge (4"X3" Lift-off h......
CPVC Cts ASTM D2846 Pipe Fitting High Pressure Pump Universa......
Sabiki Rigs Sabiki Hooks for Fishing Products Octopus Hooks
Home Gym Commercial Fitness Equipment Medipull Gym Machine R......
Portable Solar Power System for Home Use
Koyo Taper Roller Bearing 33005
Siecc Hot Sales Metal Sheet Cut 4000mm Length CNC V Grooving......